A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2015
At a glance
- Drugs Farletuzumab (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Morphotek
- 10 Jun 2017 Biomarkers information updated
- 09 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov record (NCT00318370).
- 09 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record (NCT00318370).